Latent Tuberculosis Infection: Clinical Trials

4 trials for Latent Tuberculosis Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed. 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 44Active not recruiting 2, Completed 2

Follow Latent Tuberculosis Infection: new trials by email Literature Review of Latent Tuberculosis Infection trials Research Report on Latent Tuberculosis Infection

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial of Mica
Mycobacterium Vaccae for Injection - Latent Tuberculosis Infection
Phase 4Active not recruitingAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.68002023-04-192024-06-25
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected - Latent Tuberculosis Infection
Phase 4CompletedAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.75002023-04-172024-09-19
Latent Tuberculosis in Type 2 Diabetes
Rifapentine and Isoniazid for 3 months, Isoniazid (INH) daily for 9 months - Latent Tuberculosis Infection
Phase 4Active not recruitingTaichung Veterans General Hospital5522018-04-182025-03-13
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
Preventive treatment with Isoniazid., Preventive treatment with Isoniazid - Latent Tuberculosis Infection
Phase 4CompletedHospital Universitari de Bellvitge8712010-07-012016-05-27

Narrower conditions

Latent Tuberculosis (4)  ·  Diabetes Mellitus (1)  ·  Tuberculosis (1)

Broader conditions

Actinomycetales Infections (4)  ·  Bacterial Infections (4)  ·  Bacterial Infections and Mycoses (4)  ·  Gram-Positive Bacterial Infections (4)  ·  Infections (4)  ·  Latent Infection (4)  ·  Mycobacterium Infections (4)  ·  Tuberculosis (3)  ·  Endocrine System Diseases (1)  ·  Glucose Metabolism Disorders (1)  ·  Metabolic Diseases (1)  ·  Nutritional and Metabolic Diseases (1)

Interventions

Injections (2)  ·  Isoniazid (2)  ·  rifapentine (1)

Sponsors

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (2)  ·  Hospital Universitari de Bellvitge (1)  ·  Taichung Veterans General Hospital (1)

Countries

China (2)  ·  Spain (1)  ·  Taiwan (1)

Top investigators

Yi Mo, Master (2)  ·  I-Te Lee (1)  ·  Miguel Santin, MD (1)

Results publications

PMID 29020191, PMID 40560769

NIH funding

2009 (1)